INDIANAPOLIS Eli Lilly reported the receipt of a not-approvable letter on Thursday from the Food and Drug Administration for Zyprexa long-acting injection for the treatment and maintenance treatment ...
In clinical trials, Zyprexa LAI had a safety profile similar to oral olanzapine, with the exception of post- injection excessive sedation events, which also include dizziness, confusion and altered ...
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE ...
PARSIPPANY, N.J. and TEL AVIV - Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Medincell (Euronext:MEDCL) announced today that the U.S. Food and Drug Administration has accepted their ...
June 18 (Reuters) - The U.S. Food and Drug Administration is investigating the cases of two individuals who died after injections with Eli Lilly and Co.'s long-acting treatment for schizophrenia, ...
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results